ROIV Nasdaq Russell 1000 Earnings call
Roivant Sciences (ROIV) · Q4 2026 results
Share price: $41.85 · 2026-11-11
Results Q4 2026 vs Q2 2026 · previous quarter · published 20 May 2026 and 10 Nov 2025
Management sounded restrained, in its script and in answers to analysts.
Only a basic analysis is available for this company at the moment.
1 · Numbers
—
No financial figures for this pair
Outlook given
2 · How management spoke
Restrained
Less upbeat than 78% of company calls
Answers to analysts: restrained, in line with the script.
Similar to last call.
3 · What stood out
Guidance
$2.25 billion Moderna settlement announced earlier this quarter, with the first tranche expected to be received.
Valuation
Reverse DCF. Free cash flow from the last full fiscal year, grown for 10 years, discounted back, plus a terminal value. “Implied growth” is the rate the current price assumes.
Valuation unavailable: free cash flow and profit were negative in the last full year and on average over the last three, so there is nothing to discount.
Current price
$41.85
close of 2026-11-11
Revenue growth, 3 years
−36.0% a year
compound annual rate (CAGR)
Free cash flow 2024
−$0.8B
Free cash flow 2025
−$0.8B
Free cash flow 2026
−$0.8B
Read between the lines
-
Guidance
Two late-stage trials are expected to move forward this year, with one beginning and another reporting data.
Source quote
“The Phase III study in cutaneous sarcoidosis, we expect to begin this year as well, and we expect the NIU Phase III top line data in the back...”
-
Dropped
In total is a bit less than half of Moderna's total global COVID vaccine sales and Moderna's total global COVID…
Source quote
“in total is a bit less than half of Moderna's total global COVID vaccine sales and Moderna's total global COVID... Moderna sales of COVID vaccines in the U.S. And so -- and then what Moderna has claimed in their own briefings is that we asked for about $5 billion in damages in the U.S.”
Tone
How upbeat the language was, compared with other companiesiTone counts positive minus negative finance words, adjusted for length. Executives mostly speak positively, so the labels compare each call with every company's latest call: “typical” is the middle third, “very upbeat” the top tenth, “cautious” the bottom tenth.. Dot: Q4 2026. Ring: Q2 2026.
Script and answers carried a similar tone, so the script's message held up under questioning.
Sentences that drove the tone
“A single dose of mosliciguat reduced PVR in these patients early and sustained through the 3-hour observation period with a mean PVR reduction of greater than 30% and a mean...”
“It's a really tough disease that in addition to pain causes itch burning, redness, scaling [indiscernible] hair loss.”
“So we're excited to see the commercial enthusiasm and excited to see these patients have access to some of the [indiscernible] benefit already, and we're hoping to add to that.”
Topics
Most discussed now
- Pretty good sense for what Roivant Sciences has got
- New Typically, SGC is activated when nitric oxide engages SGC in the presence of heme and CGMP is then produced.
- Over time, drugs with newer mechanisms were approved, the combination therapy involving multiple mechanisms of...
- With treatment-emergent adverse events being mild to moderate intensity across both groups, and all doses were well tolerated, and Roivant…
- The healthy volunteers underwent studies with single and multiple dose formats, and mosli proved to be well tolerated, active and...
Faded since Q2 2026
- Fading Roivant Sciences' position is pretty clearly laid out in its motions.
- Fading In terms of thinking about the sort of TED versus Graves' market dynamics, I'd say let's just wait and see...
Latest announcements
Official filings, newest first.
- Shareholder vote results · SEC 8-K
- Regulation FD disclosure · SEC 8-K
- Other events · SEC 8-K
- Regulation FD disclosure · SEC 8-K
- Results of operations · SEC 8-K
- Results of operations · SEC 8-K
- Results of operations; Regulation FD disclosure · SEC 8-K
- Material agreement; Regulation FD disclosure; Other events · SEC 8-K